AI Insight
This article examines how acute infections from common respiratory viruses like influenza and SARS-CoV-2 may promote cancer progression through inflammation-driven mechanisms. Recent experimental evidence shows that acute infection-triggered inflammatory responses can reprogram immune cells and remodel tissue environments in ways that favor tumor growth, survival, and spread, though these infections can also sometimes elicit anti-tumor responses. Understanding how infections differentially affect immune programs could inform future cancer treatment strategies.
Why it matters
The findings suggest that acute viral infections may accelerate cancer progression in patients, which could influence clinical decisions about infection prevention and management in cancer patients. This research may lead to new therapeutic approaches that target infection-induced inflammatory pathways to prevent tumor advancement.
Understand the Science
by Felipe Valença-Pereira, Bryan Johnson, James DeGregori, Mercedes Rincon
Chronic infections are associated with cancer incidence and progression in human epidemiological data, but less is known about how such infections might promote cancer progression. Recent data implicate acute infection with common respiratory viruses, such as influenza and SARS-CoV-2, in cancer progression, providing evidence that infection-driven inflammation can promote tumor expansion and dissemination in experimental systems. The resulting acute inflammatory cascade and dynamic immune cell reprogramming can rapidly remodel the tissue microenvironment to favor cancer cell survival, growth, and evasion of immune elimination. However, acute infections can also elicit anti-tumor immune responses. Defining how infections differentially skew immune programs to promote or restrain cancer progression will therefore be essential for developing future strategies to target this disease.
Source: Does acute inflammation triggered by infection promote cancer progression?